symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
NAMS,7.48,-0.26146,106300,615785794,0,7.03-32.88,-0.13,NewAmsterdam Pharma Company N.V.,USD,0001936258,,,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.newamsterdampharma.com,"NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.","Dr. Michael Harvey Davidson FACC, Facc., Facp., M.D.",Healthcare,NL,22,31 35 206 2971,Gooimeer 2-35,Naarden,,1411 DC,,0,https://financialmodelingprep.com/image-stock/NAMS.png,2021-02-09,False,False,True,False,False
